Representative Transactions

 

  • Sale of The ForeFront Group, Inc., to CBT Group in 1998 for $160 million, while serving as VP Corporate Development and General Counsel.

  • Taking The ForeFront Group, Inc., and SunPharm Corp. public in the mid-1990’s.

  • Representing Triplex Pharmaceuticals in connection with the three-way merger between it, Argus Pharmaceuticals, a public Nasdaq listed company, and Oncologix to form Aronex Pharmaceuticals.

  • Representing the merged entity, Aronex Pharmaceuticals for several years, and the ultimate sale of Aronex to Genzyme.

  • Representing Chrysalis Biotechnology in connection with the exclusive license of its technology to Abbott and the return of the technology.

  • Representing Chrysalis Biotechnology in connection with its sale of assets to OrthoLogic Corp.

  • Representing Repros Therapeutics, Inc., a public biotech company located in The Woodlands, Texas in connection with its $85 million public underwritten offering in 2012.

  • Representing Repros Therapeutics in 2004 in connection with its reverse Dutch auction tender offer.

  • Serving on the Board of Directors of Repros Therapeutics, a public Nasdaq company, from 2005 to 2009.

  • Representing Pernix Therapeutics, a public Nasdaq company in connection with its acquisition of Somaxen, a publicly traded company.

  • Representing the founder of SunBiopharm (a publicly traded company) in connection with the formation of the company, the exclusive license of the technology from the University of Florida, and its initial corporate matters and financing transactions.

  • Representing QSpex Technologies, Inc., an Essex Woodlands Health Ventures portfolio company located in Alpharetta, Georgia, following its initial investment on all general corporate and compliance matters and financings.

  • Representing Essex Woodlands Health Ventures, a leading life science industry venture capital firm, in connection with its investment into a startup company and concurrent merger of that entity with another much larger entity that is now public.

  • Representing Dialectic Therapeutics, Inc., a start-up in its in-license of cutting-edge cancer therapeutics from the Universities of Arkansas and Florida, and its initial financing.

  • Representing a platform technology for online investing in energy deals under the JOBS Act and related innovative crowdfunding rules and regulations, and serving on its Board as Chairman, and more recently leading its merger with Paleo Energy Resources, a Toronto Stock Exchange company.